Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 4:35 p.m. ET in New York, New York.
纽约,2024年5月7日(GLOBE NEWSWIRE)——应用疗法公司(纳斯达克股票代码:APLT)是一家处于临床阶段的生物制药公司,该公司正在开发一系列针对未满足高度未满足医疗需求的分子靶标的新型候选药物。该公司今天宣布,它将在美国东部时间2024年5月14日星期二下午 4:35 在新州参加2024年加拿大皇家银行资本市场全球医疗保健会议的炉边谈话纽约,纽约。
A live webcast for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at . A replay of the webcast will be archived on the Company's website for 90 days following the event.
该活动的网络直播可在应用疗法网站 “投资者关系” 部分下的 “活动” 页面上观看,网址为。网络直播的重播将在活动结束后的90天内在公司网站上存档。
About Applied Therapeutics
关于应用疗法
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Applied Therapeutics是一家处于临床阶段的生物制药公司,正在开发一系列针对经过验证的分子靶标的新型候选药物,以应对大量未满足的医疗需求。该公司的主要候选药物govorestat是一种新型的中枢神经系统渗透剂Aldose还原酶抑制剂(ARI),用于治疗中枢神经系统罕见的代谢性疾病,包括半乳糖血症、SORD缺乏症和 PMM2-CDG。该公司还在开发 AT-001,一种新型的强效急性呼吸道感染,用于治疗糖尿病心肌病(dBCM),一种致命的心脏纤维化。临床前产品线还包括 AT-003,这是一种用于治疗糖尿病视网膜病变的急性呼吸道感染,旨在通过口服给药时穿过眼背。
To learn more, please visit and follow the company on Twitter @Applied_Tx.
要了解更多信息,请在 Twitter 上访问并关注该公司 @Applied_Tx。
Contacts
联系人
Investors:
Maeve Conneighton
(212) 600-1902
appliedtherapeutics@argotpartners.com
投资者:
Maeve Conneighton
(212) 600-1902
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
媒体:
media@appliedtherapeutics.com